Holen Sie sich die Stockscreener-App
1.25
3.31%
0.04
Handel nachbörslich:
1.28
0.03
+2.40%
Schlusskurs vom Vortag:
$1.21
Offen:
$1.23
24-Stunden-Volumen:
4.44M
Relative Volume:
1.66
Marktkapitalisierung:
$3.16M
Einnahmen:
$212.10K
Nettoeinkommen (Verlust:
$-40.19M
KGV:
-0.000235
EPS:
-5313.2836
Netto-Cashflow:
$-13.92M
1W Leistung:
-23.31%
1M Leistung:
-8.09%
6M Leistung:
-97.44%
1J Leistung:
-99.99%
1-Tages-Spanne:
$1.18
$1.33
1-Wochen-Bereich:
$1.11
$1.82
52-Wochen-Spanne:
$1.11
$27,200.00
Aditxt Inc Stock (ADTX) Company Profile
Firmenname
Aditxt Inc
Sektor
Branche
Telefon
909-488-0844
Adresse
737 N. FIFTH STREET, SUITE 200, RICHMOND
Vergleichen Sie ADTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
1.25 | 3.16M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aditxt Inc Aktie (ADTX) Neueste Nachrichten
Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting - Benzinga
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board - citybiz
Aditxt Inc. Strengthens Board with Appointment of Evofem CEO Saundra Pelletier - citybuzz -
Aditxt names Evofem CEO to its board, eyes women’s health market By Investing.com - Investing.com South Africa
Aditxt names Evofem CEO to its board, eyes women’s health market - Investing.com India
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board Of Directors - MarketScreener
Aditxt (ADTX) Welcomes Saundra Pelletier to Its Board | ADTX Stock News - GuruFocus
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors | ADTX Stock News - GuruFocus
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors - Business Wire
Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, - GuruFocus
Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO Of Adimune, And Chris Mitton, President Of Pearsanta, Will Join Aditxt Weekly Update On June 6 - MarketScreener
Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6 - Bluefield Daily Telegraph
Healthcare Innovation Leaders From Evofem, Adimune, and Pearsanta Preview New Developments at Aditxt Update - Stock Titan
Aditxt (NASDAQ:ADTX) Shares Down 8.1% – Time to Sell? - Defense World
Aditxt Highlights Strategic Partnership with Evofem Biosciences - TipRanks
ADTX stock plunges to 52-week low, touches $1.5 amid steep decline By Investing.com - Investing.com South Africa
ADTX stock plunges to 52-week low, touches $1.5 amid steep decline - Investing.com Nigeria
Stocks In Play: Appili Therapeutics Inc. By Baystreet.ca - Investing.com Canada
Appili Therapeutics Inc. - Baystreet.ca
Appili Therapeutics Ends Agreement with Aditxt, Secures Loan Extensions - TipRanks
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. - The Manila Times
Options Volatility and Implied Earnings Moves Today, May 29, 2025 - The Globe and Mail
Aditxt secures $233K loan from CEO Albanna - Investing.com Australia
Aditxt secures $233K loan from CEO Albanna By Investing.com - Investing.com South Africa
Aditxt Issues Unsecured Promissory Note in Strategic Move - TipRanks
Aditxt (ADTX) Cancels Acquisition Agreement with Appili Therapeu - GuruFocus
Aditxt Discusses Strategic Focus and Growth Plans - TipRanks
Aditxt to Scrap Merger Deal With Appili Therapeutics - marketscreener.com
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics | ADTX Stock News - GuruFocus
Aditxt Announces Termination Of Arrangement Agreement With Appili Therapeutics - marketscreener.com
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. - The Manila Times
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics - Eagle-Tribune
Aditxt, Inc. SEC 10-Q Report - TradingView
Aditxt (NASDAQ:ADTX) Shares Down 5.5% – What’s Next? - Defense World
Aditxt Highlights Progress of ADI-100TM in Autoimmune Treatment - TipRanks
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Quantisnow
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, - GuruFocus
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department - GuruFocus
Aditxt secures $256K through senior note sales By Investing.com - Investing.com Nigeria
Aditxt secures $256K through senior note sales - Investing.com
Aditxt’s Subsidiary Pearsanta Gets IRB Approval - TipRanks
Finanzdaten der Aditxt Inc-Aktie (ADTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aditxt Inc-Aktie (ADTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):